The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome

Mutations in CXCR4 cause severe leukopenia in myelokathexis or WHIM syndrome. Plerixafor inhibits binding of CXCR4 to its ligand CXCL12. We investigated the effects of plerixafor (0.04 to 0.24 mg/kg) administered at 2-4 day intervals in 6 patients. Outcome measures were the patients' complete b...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dale, David C., Bolyard, Audrey Anna, Kelley, Merideth L., Westrup, Ernest C., Makaryan, Vahagn, Aprikyan, Andrew, Wood, Brent, Hsu, Frank J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3673761/
https://ncbi.nlm.nih.gov/pubmed/21835955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-06-360586
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados